News
15.04.2024 news
Indivumed Omics Hub and Clinical Network Collaborations Powering Precision Medicine Research Publications
Indivumed GmbH announced the fourth research publication enabled by the Indivumed Omics Hub. An interface for members of the Indivumed Global Clinical Network, the Omics Hub provides clinicians with direct access to curated multi-omics data derived from their patients. With access to both individual and cohort data, the Omics Hub enables quick and efficient precision oncology research.
Indivumed Omics Hub and Clinical Network Collaborations Powering Precision Medicine Research Publications Mehr erfahren11.12.2023 news
Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg
Onco AI-Med is an international collaborative alliance founded by Indivumed to advance personalized medicine in cancer by bringing together the combined knowledge and experience of oncologists from leading cancer clinics and research institutions around the world. Indivumed Therapeutics welcomed members of the Oncology Alliance For Individualized Medicine to its global headquarters in Hamburg, Germany for the Onco AI-Med annual board meeting.
Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg Mehr erfahren07.12.2023 news
BIO Deutschland Yearbook 2023/2024
We are pleased to again be featured in the BIO Deutschland Yearbook for 2023/2024 and proud to be a part of the rapidly growing European biotech industry, looking forward to continuing our success in 2024. Read our feature interview and profile here.
BIO Deutschland Yearbook 2023/2024 Mehr erfahren28.11.2023 news
Standardizing tissue quality: Your key to accurate early discovery insights
In precision oncology, tissue quality plays a pivotal role in maintaining data integrity. We explore the impact of standardizing tissue collection and processing on data quality, and how this helps enhance patient outcomes as well as our understanding of cancer.
Standardizing tissue quality: Your key to accurate early discovery insights Mehr erfahrenEvents
We look forward to meeting you at BIO International in San Diego in June.
Meet our VP Business Development Hans Vanhooren on site and get in touch with him in San Diego from June 3-6.
Join us at ASCO Annual Meeting in Chicago.
Come and visit us at ASCO Annual Meeting in Chicago, May 31 - June 4, 2024. We look forward to meeting you at our booth no. 32137.
Publications and Posters
30.04.2024 publication
Scimeca, M. et. al Molecular profiling of a bladder cancer with very high tumour mutational burden, Cell Death Discovery 10:202 (2024)
Scimeca, M. et. al Molecular profiling of a bladder cancer with very high tumour mutational burden, Cell Death Discovery 10:202 (2024) Mehr erfahren08.04.2024 poster
Poster Bischof et al. 2024 Deciphering chromosomal instability in consensus molecular Subtypes (CMS) in CRC: Insights from an integrative multi-omics approach
Poster Bischof et al. 2024 Deciphering chromosomal instability in consensus molecular Subtypes (CMS) in CRC: Insights from an integrative multi-omics approach Mehr erfahren21.03.2024 publication
Scimeca, M. et al. Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma, Discover Oncology 15:80 (2024)
Scimeca, M. et al. Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma, Discover Oncology 15:80 (2024) Mehr erfahren16.01.2024 publication
Mengting Zhu et. al Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype Discover Oncology 15:10 (2024)
Mengting Zhu et. al Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype Discover Oncology 15:10 (2024) Mehr erfahren
LITERATURE
VIDEOS
In Focus:
Company Vision – Interview with Prof. Dr. Hartmut Juhl, Indivumed Therapeutics
In Focus:
Clinical Network - Interview with Nina Gabelia (MB, MPH), Indivumed Therapeutics
In Focus:
Target Discovery - Interview with Dr. Jobst Landgrebe, Indivumed Therapeutics
In Focus:
Target Validation - Interview with Dr. Jonathan Woodsmith & Dr. Daniel Pohlmann, Indivumed Therapeutics
In Focus:
Omics Hub - Interview with Dr. Julia Bischof & Dr. Gerry Melino, Indivumed Therapeutics
In Focus:
Onco AI-Med - Interview with Dr. John Marshall, Chairman Onco AI-Med Advisory Board
Onco AI-Med:
Board Meeting Summary – Interviews with Dr. John Marshall, Prof. David Gallagher & Dr. Sun Young Rha
Onco AI-Med:
Board Meeting Summary – Interviews with Dr. John Marshall, Dr. Carlos Sampaio & Dr. David Kerr